Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy

Exclusion Criteria

• •Bilateral breast cancer, inflammatory breast cancer, or clinically stage IV (metastatic) breast cancer.
• •Any prior systemic targeted therapy, chemotherapy, endocrine therapy, biologic therapy, radiotherapy, or immunotherapy for any reason.
• •Any of the following comorbidities, medical histories, or treatment histories:
• •Known or suspected interstitial pneumonitis; or moderate to severe pulmonary disease severely affecting respiratory function, such as severe asthma or severe chronic obstructive pulmonary disease (COPD).
• •Serious cardiovascular or cerebrovascular disease, including but not limited to New York Heart Association (NYHA) class II or higher heart failure (including class II), myocardial infarction or cerebrovascular accident (including cerebral ischemia or symptomatic cerebral infarction) within 3 months before first dosing, or persistent arrhythmia of grade \>= 2.
• •Severe systemic infection (e.g., requiring intravenous antibiotics, antifungal agents, or antiviral drugs according to clinical practice standards), or unexplained fever \> 38.5 degrees C during screening or before first dosing.
• •Clinically significant bleeding symptoms within 1 month before signing informed consent, or definite bleeding tendency, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or baseline fecal occult blood of ++ or above.
• •Known hypersensitivity or intolerance to the investigational medicinal products or their excipients.
• •Any other malignancy within the previous 5 years, except cured cervical carcinoma in situ or non-melanoma skin cancer.
• •Pregnancy or lactation, or refusal by women of childbearing potential to use appropriate contraception during the trial.
• •Participation in another clinical trial within 30 days before the first dose of study drug.
• •Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in the study.